Ryuji Yasumatsu

Prof. Ryuji Yasumatsu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2022 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
RJRina Jiromaru
Rina Jiromaru
TNTakashi Nakagawa
Takashi Nakagawa
RYRyuji Yasumatsu
Ryuji Yasumatsu
Nasopharyngeal carcinoma (NPC) has seen improved treatment outcomes and a decrease in incidence worldwide in recent years due to developments in medicine and improved public health. However, 70% of cases are still diagnosed at advanced stages and these advanced NPC cases show a poor prognosis. Reports on current and future treatment in advanced NPC are summarized. Chemoradiotherapy is the mainstay of treatment for advanced NPC. The administration of platinum agents as a concurrent drug and intensity modulated radiotherapy (IMRT) is the most appropriate irradiation method, and is associated with high local control rates. For induction and adjuvant chemotherapy, platinum-based two- or three-drug combination chemotherapy is recommended. The tumour volume, plasma Epstein-Barr virus (EBV)-DNA levels, and the tumour site are used to determine the indication for adjuvant and neo-adjuvant chemotherapy. The tolerability of induction chemotherapy is controversial, and the indications and timing should be carefully considered in each case. Chemotherapy is used for patients with distant metastasis. Gemcitabine/cisplatin is the first-line regimen. The efficacy of immune checkpoint inhibitor (ICI) treatment has recently been reported for NPC and, as in other areas of the head and neck, it is expected to be effective for patients with recurrent/distant metastasis. Trials are underway for various uses of ICIs, including induction chemotherapy, postoperative treatment, and use in combination with chemoradiotherapy. Immunotherapy for NPC, an EBV-associated cancer, has been reported to have some efficacy with immunotherapy used in other EBV-associated cancers. Immunotherapy may be introduced for NPC in the future, depending on the results of clinical trials. Future changes in the treatment of NPC are expected to include risk classification based on plasma EBV-DNA levels and the development of personalized treatment with individual selection of timing and type of therapy.

28 July 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TWTakahiro Wakasaki
Takahiro Wakasaki
TMTomomi Manako
Tomomi Manako
RYRyuji Yasumatsu
Ryuji Yasumatsu
HHHirotaka Hara
Hirotaka Hara
STSatoshi Toh
Satoshi Toh
TNTakashi Nakagawa
Takashi Nakagawa
Objectives: The benefit of sequential therapy after immune checkpoint inhibitor (ICI) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) has been recently reported. Furthermore, there is a growing interest in the impact of cetuximab (Cmab)-containing salvage chemotherapy (SCT) and the therapeutic efficacy and adverse events (AEs) of Cmab administration prior to ICI administration. Materials and methods: We retrospectively reviewed the medical records of 52 patients with R/M HNSCC treated with SCT (weekly paclitaxel [PTX], n = 7, or weekly PTX and Cmab [PC], n = 45). Results: The objective response rate (ORR) and a disease control rate (DCR) was 53.3% and 91.1% in the PC group and 42.9% and 57.1% in the PTX group, respectively. There was a significant difference in the DCR between the PC and PTX groups (p = 0.0143). The overall survival (OS) and progression-free survival were significantly better in the PC group than in the PTX group. On the other hand, the incidence of drug-induced interstitial pneumonia (DI-IP) in R/M HNSCC patients who received SCT was 21.2%. Patients in the PC group were divided according to whether they received Cmab (Group A) or did not receive Cmab (Group B) as palliative therapy prior to ICIs. Group B had a significantly better OS than Group A. Furthermore, our findings suggest that the incidence rate of DI-IP during SCT might be higher in Group B. Conclusion: Although PC following ICIs shows dramatic efficacy, careful monitoring of AEs, including DI-IP, is recommended.

3 March 2024 in Cancer Diagnosis & Prognosis
Verified
Journal Article
Closed access
RJRina Jiromaru
Rina Jiromaru
RYRyuji Yasumatsu
Ryuji Yasumatsu
MMMioko Matsuo
Mioko Matsuo
KHKazuki Hashimoto
Kazuki Hashimoto
RKRyunosuke Kogo
Ryunosuke Kogo
TNTakashi Nakagawa
Takashi Nakagawa
Background/Aim: There is limited evidence about the significance of head and neck surgical observation at the time of diagnosis and follow-up of oral cancer after treatment. The aim of this study was to elucidate the prognosis and prognostic factors of oral squamous cell carcinoma (OSCC), analyze cases of double cancers, and highlight the importance of examinations during both diagnosis and post-treatment for OSCC. Patients and Methods: We performed a retrospective analysis of 272 OSCC cases treated for the first time during a 10-year period from April 2013 to March 2023 at Kyushu University Hospital. Information obtained in the clinical setting, such as age, stage, prognosis, and presence of double cancers, was used in the analysis. Results: The mean age of 272 patients was 69 years; 203 patients were males and 69 were females. The most common oral cancer sites were the tongue (54.4%). The 5-year overall survival rate was 63.8%. Double cancer was found in 93 patients (34.2%). Synchronous double cancers were found in 38 patients (14.0%), 50% of whose cancer types were head and neck cancers. Conclusion: We analyzed 272 OSCC patients treated at the Kyushu University Hospital, and the results were comparable to those reported by other institutions. Tumor site, age, and stage were identified as prognostic factors. Half of the patients with synchronous double cancers had head and neck cancer, and 3-10% of patients with double cancers after treatment for OSCC also had head and neck cancer, suggesting the importance of otorhinolaryngological observation at the time of the diagnosis and after treatment.

1 September 2025 in Cancer Diagnosis & Prognosis
Verified
Journal Article
Open access
TKTakayuki Kimura
Takayuki Kimura
DADaisuke Abe
Daisuke Abe
MKMutsukazu Kitano
Mutsukazu Kitano
SKSatoru Koike
Satoru Koike
MUMasahiro Umemoto
Masahiro Umemoto
RYRyuji Yasumatsu
Ryuji Yasumatsu
Background/Aim: Poor nutritional status is one of the key contributing factors to sarcopenia, which negatively influences postoperative complications and clinical outcomes in patients with head and neck squamous cell carcinoma (HNSCC). This study aimed to investigate the potential association between sarcopenia and clinical outcomes in patients with recurrent and/or metastatic HNSCC treated with immune checkpoint inhibitors (ICIs). Patients and Methods: A retrospective review was conducted on the medical records of 119 patients with recurrent and/or metastatic HNSCC who received ICI therapy. Results: The objective response rates (ORRs) were 30.7% in the non-sarcopenia group and 15.8% in the sarcopenia group, showing a statistically significant difference between the two groups (p=0.048). Patients with good performance status (PS), absence of sarcopenia, and distant metastasis exhibited significantly longer overall survival (OS) compared to those with poor PS, sarcopenia, and locoregional recurrence, respectively (p=0.014, p=0.003, p=0.026). Multivariate analysis identified sarcopenia and locoregional recurrence as independent prognostic factors for OS. The incidence of immune-related adverse events (irAEs) did not significantly differ between patients with and without sarcopenia. Conclusion: These findings underscore the detrimental impact of sarcopenia on the efficacy of immune checkpoint inhibitor therapy in patients with recurrent and/or metastatic HNSCC. Careful consideration of sarcopenia is warranted in the clinical management of these patients.

29 October 2025 in In Vivo
Verified
Journal Article
Open access
PDF file
TKTakayuki Kimura
Takayuki Kimura
SKSatoru Koike
Satoru Koike
HTHisatomo Tamaki
Hisatomo Tamaki
KMKazuhiro Miyamoto
Kazuhiro Miyamoto
SIShusuke Iwamoto
Shusuke Iwamoto
RYRyuji Yasumatsu
Ryuji Yasumatsu
Background/Aim: Sinonasal papilloma is a histologically benign tumor that demonstrates locally aggressive behavior, with a propensity for recurrence and potential for malignant transformation. This study aimed to evaluate the clinical characteristics, recurrence patterns, and malignant transformation of sinonasal papillomas and to propose appropriate follow-up strategies. Patients and Methods: A retrospective analysis was conducted on 83 patients diagnosed with sinonasal papilloma at our institution. Clinical features, surgical treatments, recurrence intervals, and oncologic outcomes were analyzed. Tumors were staged using the Krouse classification for benign cases and UICC TNM staging for carcinoma-associated with papilloma cases. Results: Among 83 patients (62 men, 21 women; median age 68), 74 (89.2%) were diagnosed as benign papillomas and nine (10.8%) as carcinoma-associated with papilloma. The recurrence rate among benign cases was 14.9% (11/74), with a median time to recurrence of 5 years and two months. Recurrence intervals exhibited a trimodal distribution: within two years (36.4%), between 2-10 years (36.4%), and after 10 years (27.3%). Malignant transformation occurred in one case (1.2%), and eight additional cases were found to be associated with carcinoma. Five of these were initially misdiagnosed as benign, underscoring the diagnostic limitations of imaging modalities. Krouse T3/T4 lesions were more frequently associated with recurrence and malignancy. Approximately 48.6% of patients discontinued follow-up, often before reaching the threshold for late recurrence. Conclusion: Sinonasal papillomas require long-term surveillance beyond five years due to their potential for late recurrence and malignant transformation. Preoperative suspicion of malignancy remains challenging, particularly in Krouse T3 lesions. Clinicians should consider extended follow-up, especially in patients with advanced tumor stage, and adopt a tailored surgical strategy to achieve complete resection. Patient education regarding recurrence risk is essential for optimizing long-term outcomes.

2 May 2023 in Cancer Diagnosis & Prognosis
Verified
Journal Article
Closed access
MKMutsukazu Kitano
Mutsukazu Kitano
SKSatoru Koike
Satoru Koike
HTHisatomo Tamaki
Hisatomo Tamaki
SIShusuke Iwamoto
Shusuke Iwamoto
KMKazuhiro Miyamoto
Kazuhiro Miyamoto
RYRyuji Yasumatsu
Ryuji Yasumatsu
Background/Aim: Sarcopenia has an adverse effect on postoperative complications and prognoses in head and neck cancer. This study focused on hypopharyngeal and laryngeal cancer patients with sarcopenia and analyzed the body composition following treatment when the larynx was preserved and when total laryngectomy was performed to examine the usefulness of laryngectomy. Patients and Methods: We retrospectively reviewed 88 primary hypopharyngeal and laryngeal cancer patients aged 65 years or older with cT2N0M0 or higher who visited our department. Results: There were no significant differences in the 3-year overall survival rate and the 1-year local control rate between the laryngeal preservation group and laryngectomy group. The average change one year following treatment in the laryngeal preservation group, when compared to prior to treatment, was a significant decrease in the body weight (BW) of -0.035, skeletal muscle mass (SMM) of -0.030, skeletal muscle mass index (SMI) of -0.026, body mass index (BMI) of -0.034, and grip strength (GS) of -0.066. The average change one year following treatment in the laryngectomy group, compared with prior to treatment, was an increase in BW of +0.028, SMM of +0.026, SMI of +0.008, BMI of +0.032, and GS of +0.026. Although no changes in serum biochemical testing after treatment were observed in the laryngeal preservation group, albumin, transferrin, and transthyretin all exhibited significant improvement or a tendency toward improvement in the laryngectomy group. The patients with sarcopenia before treatment in the laryngeal preservation group had a significantly higher incidence of aspiration pneumonia. Conclusion: The presence or absence of sarcopenia before starting treatment is considered to be an index for selecting total laryngectomy.